Cholesterol - A putative endogenous contributor towards Parkinson's disease

Area of Science:

• Neuroscience
• Metabolic Disorders
• Neurodegenerative Diseases

Background:

• Elevated cholesterol and oxysterols are linked to metabolic syndromes and Alzheimer's disease.
• Emerging research suggests oxysterols and excess cholesterol may induce Parkinsonian pathologies in vitro.
• Oxysterols can cause alpha-synuclein aggregation and dopamine neuron destruction, potentially via oxidative stress.

Purpose of the Study:

• To review neuropathological mechanisms linking excess cholesterol/metabolites to Parkinson's disease (PD).
• To evaluate the conflicting clinical evidence regarding cholesterol levels and PD incidence.
• To explore the potential of cholesterol-lowering statin therapy in PD prevention.

Main Methods:

• Review of in vitro, animal, and clinical studies on cholesterol, oxysterols, and PD.
• Analysis of studies investigating high-fat diets' impact on PD models.
• Examination of research on statin efficacy in relation to PD.

Main Results:

• In vitro models show oxysterols induce alpha-synuclein aggregation and dopamine neuron loss.
• Clinical studies present mixed correlations between plasma cholesterol and PD incidence.
• Animal models demonstrate high-fat diets exacerbate PD pathologies, including neurodegeneration and oxidative stress.

Conclusions:

• Cholesterol and its metabolites play a complex role in PD pathogenesis, with significant in vitro evidence but less consistent clinical findings.
• Further research is needed to clarify the precise relationship between cholesterol metabolism and PD.
• Statins may offer a potential therapeutic avenue for reducing PD risk, warranting further investigation.